Alt tag
Bayer Logo Bayer Logo Bayer Logo

Welcome to Vascular Adviser

The Vascular Protection Resource

Adviser’s Picks

When should dual pathway inhibition be stopped in patients with symptomatic PAD following peripheral revascularization?
When should dual pathway inhibition be stopped in patients with symptomatic PAD following peripheral revascularization?
Thrombotic risk after endovascular revascularization
Can the risk of vascular events be reduced in patients with peripheral artery disease undergoing...
Antithrombotic protection after lower-extremity revascularization: Can clopidogrel be used alongside DPI?
Antithrombotic protection after lower-extremity revascularization: Can clopidogrel be used alongside DPI?
VA_High_CV_Low_Bleeding_Risk
Enhanced vascular protection for high-risk patients: What’s your best option?

What is ‘Vascular Protection’?

YYMMDD Author/Uploaded by

Vascular disease and its many manifestations, including coronary artery disease (CAD) and peripheral artery disease (PAD), have a major impact on the lives of millions of patients and those around them. Major advances in surgical and medical management strategies have helped healthcare professionals reduce its impact. However, despite these advances, the residual risk of major adverse cardiac events remains high. Research into innovative strategies to address this residual risk is ongoing. Whether it is through the use of different combinations of antithrombotic drugs, reducing lipid levels or other disease mediators, the area of Vascular Protection is exciting and continues to evolve.

 

PP-XAR-ALL-2054-1

Vascular Adviser: Frequently Asked Questions

Listen to the Vascular Adviser Podcast Series

anchor

The VOYAGER PAD Trial: Rationale and Results

YYMMDD Author/Uploaded by

Find out how the combined risk of lower limb ischaemia and major cardiovascular events following peripheral revascularization was reduced in patients with symptomatic PAD in the VOYAGER PAD trial

 

PP-M_RIV-ALL-0109-1

The COMPASS Trial: Rationale and Results

YYMMDD Author/Uploaded by

Find out how the risk of cardiovascular events was reduced in patients with CAD and PAD in the COMPASS trial

 

PP-XAR-ALL-0516-2

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!